The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early versus delayed initiation of salvage androgen deprivation therapy and the risk of prostate cancer-specific mortality.
 
Brandon Arvin Virgil Mahal
No Relationships to Disclose
 
Ming-Hui Chen
No Relationships to Disclose
 
Andrew A. Renshaw
No Relationships to Disclose
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; Druggablity Technologies; Placon; Tarveda Therapeutics
Consulting or Advisory Role - Astellas Pharma; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; BIND Biosciences; Druggablity Technologies; Genentech/Roche; GTx; Ipsen; Janssen; Merck; Metamark Genetics; MorphoSys; MTG Therapeutics; Omnitura; OncoCellMDX; Oncogenex; Progenity; Sanofi; Tarveda Therapeutics; Thermo Fisher Scientific
Research Funding - Amgen (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Bayer (Inst); Dendreon (Inst); Exelixis (Inst); Janssen (Inst); Medivation (Inst); Oncogenex (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties
Expert Testimony - Janssen; Sanofi
Travel, Accommodations, Expenses - Sanofi; Tarveda Therapeutics
 
Anthony Victor D'Amico
No Relationships to Disclose